This newsletter presents you the best read sessions:
1. Improved PFS and OS for switch maintenance with ramucirumab plus paclitaxel compared to continuation of chemotherapy in advanced
HER2-negative gastric or GEJ cancer: results of phase III ARMANI trial
2. Chemotherapy with liver transplantation results in better OS and PFS compared to chemotherapy alone in unresectable colorectal liver
metastases: TRANSMET trial
3. POCHI trial: combining pembrolizumab with standard therapy is effective in patients with pMMR/MSS mCRC and high tumor lymphocyte
infiltration
4. First-line 177Lu-DOTATATE treatment is effective across NET grades and locations